Section Arrow
VIRX.NASDAQ
- Viracta Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2024/12/24 12:37 EST
Last
 0.2519
+0.0192 (+8.25%)
Day High 
0.2519 
Prev. Close
0.2327 
1-M High
0.257406 
Volume 
257.92K 
Bid
0.2451
Ask
0.2519
Day Low
0.23 
Open
0.2337 
1-M Low
0.1326 
Market Cap 
9.25M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.2 
20-SMA 0.18 
50-SMA 0.19 
52-W High 1.31 
52-W Low 0.1315 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.10/-0.41
Enterprise Value
34.13M
Balance Sheet
Book Value Per Share
-0.17
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.3859-0.0172-4.27%-- 
CMNDClearmind Medicine1.64+0.42+34.43%0.16PE
CEROCERo Therapeutics Holdings0.0597+0.0092+18.22%-- 
RXRXRecursion Pharmaceuticals7.195+0.205+2.93%-- 
CDTConduit Pharmaceuticals0.0582+0.0037+6.79%-- 
Quotes are at least 15-min delayed:2024/12/24 12:37 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.